Clinical Trial Update: Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluates the efficacy of combining GLIZIGEN oral solution once daily with a vaginal gel nightly over 2 months in patients with CIN1 ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Low-grade Squamous Intraepithelial Lesion
• Papillomavirus Infection

Drugs mentioned

• Glizigen (null)

Snippet

Sponsor: Catalysis SL | Conditions: Papilloma Viral Infection, CIN1 | Phase 4 | Status: UNKNOWN